Neuraxpharm continues its European expansion with a new Brussels-based Belgian unit to be headed by country manager Pierre-Hervé Brun. The announcement adds to the more than 20 European countries where the company is recognized and established. 

Pfizer has added hundreds of off-patent products to the portfolio that it is offering on a not-for-profit basis to 45 lower-income countries under its global health equity initiative.

An IGBA research report suggests international health bodies lack an accurate picture of global essential medicines shortages due to issues with monitoring and recording.

Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.

The IGBA chair passes to Jonathan Kimball. He will head the global off-patent industry organization as it steps up its activities in global policy.

Alvotech’s Simponi rival enters Phase I trials after a dynamic year for the company’s development and commercialization program. Meanwhile, the biosimilars developer has also expanded its Japanese collaboration with Fuji Pharma.